Arvinas (NASDAQ:ARVN) CFO Sells $110,721.66 in Stock

Arvinas, Inc. (NASDAQ:ARVN) CFO Andrew Saik sold 11,139 shares of the stock in a transaction dated Monday, May 11th. The shares were sold at an average price of $9.94, for a total transaction of $110,721.66. Following the completion of the transaction, the chief financial officer owned 193,128 shares of the company’s stock, valued at $1,919,692.32. This represents a 5.45% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Andrew Saik also recently made the following trade(s):

• On Friday, February 13th, Andrew Saik sold 5,134 shares of Arvinas stock. The shares were sold at an average price of $11.89, for a total transaction of $61,043.26.

Arvinas Trading Down 3.6%

NASDAQ:ARVN opened at $9.08 on Friday. The firm has a 50-day moving average price of $10.97 and a two-hundred day moving average price of $11.67. Arvinas, Inc. has a twelve month low of $6.05 and a twelve month high of $14.51. The company has a market capitalization of $585.84 million, a P/E ratio of -2.73 and a beta of 1.79.

Arvinas (NASDAQ:ARVN) last posted its earnings results on Tuesday, May 12th. The company reported ($0.90) earnings per share for the quarter, beating the consensus estimate of ($0.95) by $0.05. Arvinas had a negative net margin of 247.54% and a negative return on equity of 44.38%. The firm had revenue of $15.60 million during the quarter, compared to the consensus estimate of $16.61 million. During the same period last year, the firm posted $1.14 EPS. The firm’s revenue for the quarter was down 91.7% on a year-over-year basis. On average, equities research analysts predict that Arvinas, Inc. will post -2.85 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the stock. Truist Financial set a $10.00 target price on shares of Arvinas in a report on Wednesday, March 18th. Citigroup raised their target price on shares of Arvinas from $21.00 to $24.00 and gave the company a “buy” rating in a report on Monday, May 4th. Zacks Research downgraded shares of Arvinas from a “hold” rating to a “strong sell” rating in a report on Monday, April 27th. Barclays raised their target price on shares of Arvinas from $18.00 to $20.00 and gave the company an “overweight” rating in a report on Wednesday. Finally, BTIG Research lifted their price target on shares of Arvinas from $16.00 to $18.00 and gave the stock a “buy” rating in a report on Wednesday. Eight equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and three have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Arvinas has a consensus rating of “Hold” and an average target price of $14.69.

Institutional Investors Weigh In On Arvinas

A number of hedge funds and other institutional investors have recently modified their holdings of ARVN. TCG Crossover Management LLC purchased a new stake in shares of Arvinas during the third quarter worth about $13,780,000. Balyasny Asset Management L.P. grew its holdings in shares of Arvinas by 469.1% during the third quarter. Balyasny Asset Management L.P. now owns 1,207,267 shares of the company’s stock worth $10,286,000 after buying an additional 995,125 shares in the last quarter. Qube Research & Technologies Ltd grew its holdings in shares of Arvinas by 154.8% during the third quarter. Qube Research & Technologies Ltd now owns 1,486,864 shares of the company’s stock worth $12,668,000 after buying an additional 903,337 shares in the last quarter. Millennium Management LLC grew its holdings in shares of Arvinas by 208.4% during the first quarter. Millennium Management LLC now owns 1,310,326 shares of the company’s stock worth $9,198,000 after buying an additional 885,483 shares in the last quarter. Finally, Armistice Capital LLC grew its holdings in shares of Arvinas by 114.3% during the third quarter. Armistice Capital LLC now owns 1,200,000 shares of the company’s stock worth $10,224,000 after buying an additional 640,000 shares in the last quarter. 95.19% of the stock is currently owned by hedge funds and other institutional investors.

Arvinas News Summary

Here are the key news stories impacting Arvinas this week:

• Positive Sentiment: BTIG Research raised its price target on Arvinas to $18 from $16 and reiterated a Buy rating, signaling continued Wall Street confidence in upside potential. Arvinas (NASDAQ:ARVN) Price Target Raised to $18.00 at BTIG Research
• Positive Sentiment: Arvinas and Pfizer’s breast cancer drug vepdegestrant was licensed to Rigel Pharmaceuticals in a deal that includes $85 million upfront and up to $320 million in milestones, which supports the value of Arvinas’ PROTAC platform and adds potential non-dilutive funding. Rigel strikes licensing deal for Pfizer and Arvinas’ breast cancer drug
• Neutral Sentiment: HC Wainwright modestly adjusted several earnings forecasts for Arvinas, including lower estimates for 2026-2029 and a small cut to FY2030 EPS, reflecting ongoing uncertainty around future profitability rather than a major new development.
• Neutral Sentiment: Arvinas recently beat Q1 EPS estimates, but revenue missed expectations and dropped sharply year over year, reinforcing that the company remains far from sustained profitability. Arvinas, Inc. (ARVN) Reports Q1 Loss, Misses Revenue Estimates
• Negative Sentiment: Recent insider selling by the CEO, CFO, CAO, and another executive may be pressuring sentiment, even though the sales were disclosed as tax-withholding transactions tied to equity vesting. CEO insider filing

Arvinas Company Profile

Arvinas, Inc (NASDAQ: ARVN) is a biopharmaceutical company focused on the development of therapies based on targeted protein degradation. Utilizing its proprietary proteolysis-targeting chimera (PROTAC®) platform, Arvinas aims to selectively eliminate disease-causing proteins rather than merely inhibit their activity. This novel approach has the potential to address a range of diseases, including oncology, neurodegeneration and inflammation, by harnessing the body’s natural protein-recycling systems.

The company’s most advanced clinical candidates address hormone-driven cancers.